Literature DB >> 717931

Life-threatening hyperkalemia induced by arginine.

D A Bushinsky, F J Gennari.   

Abstract

Marked hyperkalemia was observed during and immediately after an infusion of arginine monohydrochloride in two patients with severe hepatic disease and moderate renal insufficiency. Both patients had received brief courses of spironolactone before arginine treatment. In one of the patients, the hyperkalemia was associated with a fatal cardiac arrhythmia. Arginine has been shown to shift potassium from cells to the extracellular compartment, an effect directly related to its serum concentration. The profound hyperkalemia that occurred in these two patients is thought to be the result of an inability to metabolize the administered arginine and excrete the excess extracellular potassium. Caution is advised in administering arginine to patients with renal or hepatic insufficiency, or both.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 717931     DOI: 10.7326/0003-4819-89-5-632

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

Review 1.  Differential diagnosis of nongap metabolic acidosis: value of a systematic approach.

Authors:  Jeffrey A Kraut; Nicolaos E Madias
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

Review 2.  Rational treatment of acid-base disorders.

Authors:  M L McLaughlin; J P Kassirer
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 3.  Drug-induced electrolyte abnormalities.

Authors:  E P Brass; W L Thompson
Journal:  Drugs       Date:  1982-09       Impact factor: 9.546

4.  Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy.

Authors:  Giampiero Giovacchini; Guillaume Nicolas; Heike Freidank; Thomas L Mindt; Flavio Forrer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-07       Impact factor: 9.236

Review 5.  L-Arginine as a potential ergogenic aid in healthy subjects.

Authors:  Thiago S Álvares; Cláudia M Meirelles; Yagesh N Bhambhani; Vânia M F Paschoalin; Paulo S C Gomes
Journal:  Sports Med       Date:  2011-03-01       Impact factor: 11.136

6.  Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone.

Authors:  M I Khan
Journal:  Can Med Assoc J       Date:  1980-11-08       Impact factor: 8.262

7.  Differential diagnosis of hyperkalemia: an update to a complex problem.

Authors:  T Eleftheriadis; K Leivaditis; G Antoniadi; V Liakopoulos
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

Review 8.  Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.

Authors:  Edgar J Rolleman; Marleen Melis; Roelf Valkema; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-14       Impact factor: 9.236

9.  Diagnosing growth hormone deficiency in adults.

Authors:  Nigel Glynn; Amar Agha
Journal:  Int J Endocrinol       Date:  2012-07-26       Impact factor: 3.257

10.  Safety profile of L-arginine infusion in moderately severe falciparum malaria.

Authors:  Tsin W Yeo; Daniel A Lampah; Retno Gitawati; Emiliana Tjitra; Enny Kenangalem; Donald L Granger; J Brice Weinberg; Bert K Lopansri; Ric N Price; David S Celermajer; Stephen B Duffull; Nicholas M Anstey
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.